|
|
Palbociclib is a targeted therapy medication used primarily for the treatment of specific types of advanced or metastatic breast cancer. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, Palbociclib belongs to a class of drugs known as CDK4/6 inhibitors.
Primary Medical Use
Palbociclib 125mg is indicated for the treatment of HR-positive (hormone receptor-positive), HER2-negative (human epidermal growth factor receptor 2-negative) advanced or metastatic breast cancer. It is typically prescribed in combination with:
An aromatase inhibitor (such as letrozole) as initial endocrine-based therapy in postmenopausal women or in men.
Fulvestrant in patients whose disease has progressed following endocrine therapy.
Mechanism of Action
To understand how Palboxen 125 Mg (Palbociclib) works, it is helpful to look at the cell cycle. Cancer is characterized by uncontrolled cell division. In many breast cancers, the proteins Cyclin-Dependent Kinase 4 and 6 (CDK4/6) become overactive, driving cells to divide too quickly.
Palbociclib works by specifically blocking these proteins. By inhibiting CDK4 and CDK6, the medication halts the cell cycle at the G
1
phase, preventing the cancer cells from DNA replication and further division. This "freezes" the growth of the tumor, effectively slowing the progression of the disease.
Dosage and Administration
The 125mg dose is the standard starting strength for most patients. It is typically administered in a "3 weeks on, 1 week off" cycle:
Active Phase: One 125mg capsule or tablet taken daily for 21 consecutive days.
Rest Phase: No medication for the following 7 days to allow the body (specifically blood counts) to recover.
The medication should be taken at approximately the same time each day. If using the capsule form, it must be taken with food to ensure consistent absorption. The tablet form can generally be taken with or without food.
Clinical Benefits
Clinical trials, such as the PALOMA studies, have demonstrated that adding Palbociclib to endocrine therapy significantly extends progression-free survival (PFS). This means patients often remain on the treatment longer without their cancer worsening compared to those taking endocrine therapy alone. While it is not a cure for metastatic cancer, it serves as a vital tool in managing the disease as a chronic condition.
Side Effects and Monitoring
Because Palbociclib affects cell division, it can impact healthy cells that divide frequently, such as those in the bone marrow.
Neutropenia: The most common side effect is a decrease in white blood cells (neutrophils). This is why the "7-day rest" period is crucial. Healthcare providers will perform regular blood tests (Complete Blood Count or CBC) to monitor these levels.
Fatigue: Many patients report feeling significantly tired during the 21-day active cycle.
Infections: Due to lowered white blood cell counts, patients may be more susceptible to infections.
Other effects: Nausea, thinning hair (alopecia), diarrhea, and mouth sores are also possible.
Important Precautions
Drug Interactions: Palbociclib is metabolized by the liver enzyme CYP3A4. Patients should avoid grapefruit and Seville oranges, as these can increase the drug's concentration in the blood to dangerous levels.
Pregnancy: This medication can cause fetal harm and is not recommended for individuals who are pregnant or planning to become pregnant.
Blood Work: Strict adherence to the blood monitoring schedule is required to manage potential toxicity and adjust dosages if necessary.
Disclaimer: This information is for educational purposes and should not replace professional medical advice. Always consult with an oncologist or healthcare provider regarding specific treatments and prescriptions.
|
|
发表于 2026-5-2 13:41:05